Peter Salzmann
Chief Executive Officer chez IMMUNOVANT, INC.
Fortune : 34 M $ au 31/03/2024
Profil
Peter Salzmann is currently the Chief Executive Officer & Director at Immunovant, Inc. He is also the Chief Executive Officer at IMVT Corp.
and a Director at Corbus Pharmaceuticals, Inc. Additionally, he serves as an Independent Director at Corbus Pharmaceuticals Holdings, Inc. and as a Director at Immunovant Sciences Ltd.
Previously, Dr. Salzmann worked at Eli Lilly & Co. from 2011 to 2019, where he held the position of Head-Immunology from 2013 to 2019.
He also worked at Eli Lilly Asia, Inc. from 2008 to 2010 as the Head-Marketing.
Dr. Salzmann's education includes an undergraduate degree from Northwestern University, an MBA from Stanford Graduate School of Business, and a doctorate from Pritzker School of Medicine.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
IMMUNOVANT INC
0,72% | 17/04/2024 | 1 052 879 ( 0,72% ) | 34 M $ | 31/03/2024 |
| 22/03/2024 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Peter Salzmann
| Sociétés | Poste | Début |
|---|---|---|
| CORBUS PHARMACEUTICALS HOLDINGS, INC. | Director/Board Member | 06/03/2020 |
| IMMUNOVANT, INC. | Chief Executive Officer | 01/06/2019 |
Corbus Pharmaceuticals, Inc.
 Corbus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Corbus Pharmaceuticals, Inc. is engaged in biotechnology services. The company is headquartered in Norwood, MA. | Director/Board Member | - |
| IMVT Corp. | Chief Executive Officer | - |
Immunovant Sciences Ltd.
 Immunovant Sciences Ltd. BiotechnologyHealth Technology Part of Roivant Sciences Ltd., Immunovant Sciences Ltd. develops restorative therapies for autoimmune diseases. The private company is based in Hamilton, Bermuda. Immunovant Sciences was acquired by Health Sciences Acquisitions Corp. from Roivant Sciences Ltd. on December 19, 2019 for $863.06 million. | Director/Board Member | 01/10/2019 |
Anciens postes connus de Peter Salzmann
| Sociétés | Poste | Fin |
|---|---|---|
| ELI LILLY AND COMPANY | Corporate Officer/Principal | 01/06/2019 |
| Eli Lilly Asia, Inc. | Sales & Marketing | 01/12/2010 |
Formation de Peter Salzmann
| Northwestern University | Undergraduate Degree |
| Stanford Graduate School of Business | Masters Business Admin |
| Pritzker School of Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| ELI LILLY AND COMPANY | Health Technology |
| CORBUS PHARMACEUTICALS HOLDINGS, INC. | Health Technology |
| IMMUNOVANT, INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
Corbus Pharmaceuticals, Inc.
Corbus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Corbus Pharmaceuticals, Inc. is engaged in biotechnology services. The company is headquartered in Norwood, MA. | Health Technology |
| Eli Lilly Asia, Inc. | |
Immunovant Sciences Ltd.
Immunovant Sciences Ltd. BiotechnologyHealth Technology Part of Roivant Sciences Ltd., Immunovant Sciences Ltd. develops restorative therapies for autoimmune diseases. The private company is based in Hamilton, Bermuda. Immunovant Sciences was acquired by Health Sciences Acquisitions Corp. from Roivant Sciences Ltd. on December 19, 2019 for $863.06 million. | Health Technology |
| IMVT Corp. |
